Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 24;9(8):820.
doi: 10.3390/vaccines9080820.

Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines

Rekha R Rapaka  1 , Alan S Cross  1 , Monica A McArthur  1
Affiliations
Review

Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines

Rekha R Rapaka et al. Vaccines (Basel). .

Abstract

Using adjuvants to drive features of T cell responses to vaccine antigens is an important technological challenge in the design of new and improved vaccines against infections. Properties such as T helper cell function, T cell memory, and CD8+ T cell cytotoxicity may play critical roles in optimal and long-lived immunity through vaccination. Directly manipulating specific immune activation or antigen delivery pathways with adjuvants may selectively augment desired T cell responses in vaccination and may improve the effectiveness and durability of vaccine responses in humans. In this review we outline recently studied adjuvants in their potential for antigen presenting cell and T cell programming during vaccination, with an emphasis on what has been observed in studies in humans as available.

Keywords: APC; CD4+ T cell; CD8+ T cell; T cell; TLR; Th; adjuvant; antigen presenting cell; differentiation; memory.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Di Pasquale A., Preiss S., Silva F.M.D.O.E., Garçon N. Vaccine Adjuvants: From 1920 to 2015 and Beyond. Vaccines. 2015;3:320–343. doi: 10.3390/vaccines3020320. - DOI - PMC - PubMed
    1. Del Giudice G., Rappuoli R., Didierlaurent A.M. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin. Immunol. 2018;39:14–21. doi: 10.1016/j.smim.2018.05.001. - DOI - PubMed
    1. Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.-L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507. - DOI - PMC - PubMed
    1. Calvo-Calle J.M., Hammer J., Sinigaglia F., Clavijo P., Moya-Castro Z.R., Nardin E.H. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: Identification of a universal T cell epitope in the Plasmodium falciparum circumspo-rozoite protein. J. Immunol. 1997;159:1362–1373. - PubMed
    1. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 2001;1:209–219. doi: 10.1038/35105075. - DOI - PubMed